Catalog No.
DHG11001
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG2-lambda
Clonality
Monoclonal
Target
Tumor necrosis factor receptor superfamily member 9, CD137, 4-1BB ligand receptor, CDw137, TNFRSF9, T-cell antigen ILA, T-cell antigen 4-1BB homolog, ILA
Concentration
0.91 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q07011
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
PF-05082566, PF-2566, CAS: 1417318-27-4
Clone ID
Utomilumab
Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab, PMID: 30410017
Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer, PMID: 29549159
Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors, PMID: 28634283
A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors, PMID: 31801624
Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies, PMID: 29118009
First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20 + Non-Hodgkin Lymphomas, PMID: 32144134
Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity, PMID: 31105267
Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity, PMID: 31974274
Limited Cross-Linking of 4-1BB by 4-1BB Ligand and the Agonist Monoclonal Antibody Utomilumab, PMID: 30355497
Combination avelumab and utomilumab immunotherapy can induce diabetic ketoacidosis, PMID: 28648834
Enhancing PD-1 Blockade in Solid Tumors, PMID: 27369047
CD137 as an Attractive T Cell Co-Stimulatory Target in the TNFRSF for Immuno-Oncology Drug Development, PMID: 34064598
Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity, PMID: 22406983
A phase I/II trial of avelumab combinations with ivuxolimab, utomilumab, and radiation therapy in patients with advanced gastrointestinal malignancies., PMID:40139261
Development of a c-MET x CD137 bispecific antibody for targeted immune agonism in cancer immunotherapy., PMID:38492435
Facile generation of biepitopic antibodies with intrinsic agonism for activating receptors in the tumor necrosis factor superfamily., PMID:38168220
M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation., PMID:38091375
Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies., PMID:37864520
A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma., PMID:37851072
Costimulatory capacity of CD137 mAbs on T cells depends on elaborate CRD structures but not on blocking ligand-receptor binding., PMID:37675596
FcγR requirements and costimulatory capacity of Urelumab, Utomilumab, and Varlilumab., PMID:37575254
Axicabtagene Ciloleucel in Combination with the 4-1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11., PMID:37527011
4-1BB Targeting Immunotherapy: Mechanism, Antibodies, and Chimeric Antigen Receptor T., PMID:37433196
The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy., PMID:36727218
First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors., PMID:36302562
Development and characterization of a novel human CD137 agonistic antibody with anti-tumor activity and a good safety profile in non-human primates., PMID:36176235
A humanized 4-1BB-targeting agonistic antibody exerts potent antitumor activity in colorectal cancer without systemic toxicity., PMID:36076251
Utomilumab in Patients With Immune Checkpoint Inhibitor-Refractory Melanoma and Non-Small-Cell Lung Cancer., PMID:35983060
Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study., PMID:34687398
CD137 as an Attractive T Cell Co-Stimulatory Target in the TNFRSF for Immuno-Oncology Drug Development., PMID:34064598
First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas., PMID:32144134
Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity., PMID:31974274
A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors., PMID:31801624
Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity., PMID:31105267
Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab., PMID:30410017
Limited Cross-Linking of 4-1BB by 4-1BB Ligand and the Agonist Monoclonal Antibody Utomilumab., PMID:30355497
Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer., PMID:29549159
Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies., PMID:29118009
Combination avelumab and utomilumab immunotherapy can induce diabetic ketoacidosis., PMID:28648834
Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors., PMID:28634283
Enhancing PD-1 Blockade in Solid Tumors., PMID:27369047
Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity., PMID:22406983
For research use only. Not for human or drug use.
